# Efficacy and Safety of DMB-I (INN: Latrepirdine) in Patients With Alzheimer Type Dementia

> **NCT07251023** · PHASE3 · RECRUITING · sponsor: **Bigespas LTD** · enrollment: 450 (estimated)

## Conditions studied

- Alzheimer Type Dementia

## Interventions

- **DRUG:** DMB-I (INN: Latrepirdine)
- **DRUG:** Memantine Hydrochloride 20 MG
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07251023
- **Lead sponsor:** Bigespas LTD
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-20
- **Primary completion:** 2027-05
- **Final completion:** 2027-05
- **Target enrollment:** 450 (ESTIMATED)
- **Last updated:** 2025-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07251023

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07251023, "Efficacy and Safety of DMB-I (INN: Latrepirdine) in Patients With Alzheimer Type Dementia". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT07251023. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*